{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:09:57Z","timestamp":1762376997836,"version":"3.41.0"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Transthyretin cardiac amyloidosis (ATTR-CA) is typically a late-onset disease caused by the deposit of transthyretin amyloid fibrils throughout the heart. When this occurs, various cardiac sequelae can develop, including hypotension, conduction abnormalities, and valvular lesions. The cardiomyopathy caused by ATTR-CA (ATTR-CM) has proven difficult to treat. Until recently, symptomatic management was the only therapeutic option, and many therapies used to treat congestive heart failure were ineffective or even detrimental to patients with ATTR-CM. In addition, treatment was limited to heart and liver transplantation. As a result, prognosis was poor. Recently, a few drug therapies have come to light as potential treatment modalities for ATTR-CM, most notably tafamidis, sold under the brand names Vyndaqel and Vyndamax. After the phase III Transthyretin Amyloidosis Cardiomyopathy trial displayed the drug\u2019s efficacy, it was given breakthrough therapy designation and was approved by the Food and Drug Administration on May 6, 2019, for the treatment of ATTR-CA. This novel therapy, as well as various other therapies in the pipeline, such as inotersen and patisiran, provide hope where, until recently, there was little. Unfortunately, the exorbitant cost of these new therapies may present a barrier to long-term treatment for some patients. However, by further improving diagnostic algorithms and incorporating these new treatments into our existing therapeutic modalities, patients with ATTR-CA should be able to live far longer than previously expected. Finally, further research combining these novel treatment modalities must be done, as they may prove to be additive or even synergistic in their treatment of ATTR amyloidosis.<\/jats:p>","DOI":"10.1097\/crd.0000000000000387","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T18:33:03Z","timestamp":1629138783000},"page":"263-273","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy"],"prefix":"10.1097","volume":"29","author":[{"given":"Matthew","family":"Capustin","sequence":"first","affiliation":[{"name":"Department of Medicine, Zucker School of Medicine\/Northwell Northshore-Long Island Jewish Medical Center, Manhasset, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cardiology, New York Medicine and Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCRESAHA.117.310982","article-title":"Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.","volume":"121","author":"Muchtar","year":"2017","journal-title":"Circ Res"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/01.CIR.0000090688.49283.67","article-title":"Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans.","volume":"108","author":"Sanders","year":"2003","journal-title":"Circulation"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10741-019-09776-3","article-title":"Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.","volume":"24","author":"Rigopoulos","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.7754382","article-title":"Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.","volume":"268","author":"Monaco","year":"1995","journal-title":"Science"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40336-018-00311-2","article-title":"Cardiac amyloidosis.","volume":"7","author":"Giorgetti","year":"2019","journal-title":"Clin Transl Imaging"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing.","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"R7-20250619","first-page":"343","article-title":"Cardiac amyloidosis: the great pretender.","volume":"24","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment.","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14\u2009333 African-Americans.","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure.","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS\u2014the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13506120701815373","article-title":"Gender-related risk of myocardial involvement in systemic amyloidosis.","volume":"15","author":"Rapezzi","year":"2008","journal-title":"Amyloid"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506121003619310","article-title":"How to diagnose cardiac amyloidosis early: impact of ECG, tissue Doppler echocardiography, and myocardial biopsy.","volume":"17","author":"Piper","year":"2010","journal-title":"Amyloid"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy.","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/heartjnl-2015-308657","article-title":"Prognostic implication of relative regional strain ratio in cardiac amyloidosis.","volume":"102","author":"Senapati","year":"2016","journal-title":"Heart"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-5273(92)90115-J","article-title":"Cardiac tamponade as presentation of systemic amyloidosis.","volume":"36","author":"Navarro","year":"1992","journal-title":"Int J Cardiol"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/hrt.75.4.426-b","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation.","volume":"75","author":"Stables","year":"1996","journal-title":"Heart"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","article-title":"Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?","volume":"24","author":"Rubin","year":"2017","journal-title":"Amyloid"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis.","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly.","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum Pathol"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis.","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod Pathol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update.","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"R30-20250619","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"R31-20250619","first-page":"348","article-title":"The role of endomyocardial biopsy in the diagnosis of cardiomyopathies.","volume":"3","author":"Frustaci","year":"2002","journal-title":"Ital Heart J"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis.","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation.","volume":"49","author":"Carroll","year":"1982","journal-title":"Am J Cardiol"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1536\/ihj.15-005","article-title":"Contribution of electrocardiogram in the differentiation of cardiac amyloidosis and nonobstructive hypertrophic cardiomyopathy.","volume":"56","author":"Huang","year":"2015","journal-title":"Int Heart J"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.amjcard.2015.07.008","article-title":"Usefulness of combining electrocardiographic and echocardiographic findings and brain natriuretic peptide in early detection of cardiac amyloidosis in subjects with transthyretin gene mutation.","volume":"116","author":"Di Bella","year":"2015","journal-title":"Am J Cardiol"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.acvd.2011.10.004","article-title":"Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis.","volume":"104","author":"Mohty","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjcard.2004.04.026","article-title":"Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography.","volume":"94","author":"Ha","year":"2004","journal-title":"Am J Cardiol"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1540-8175.2012.01680.x","article-title":"Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography.","volume":"29","author":"Baccouche","year":"2012","journal-title":"Echocardiography"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis.","volume":"103","author":"Ruberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis.","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis.","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis.","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.24914","article-title":"Novel screening for transthyretin amyloidosis by using fat ultrasonography.","volume":"81","author":"Misumi","year":"2017","journal-title":"Ann Neurol"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography.","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/13506129.2013.825240","article-title":"Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.","volume":"20","author":"Damy","year":"2013","journal-title":"Amyloid"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model.","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R51-20250619","first-page":"519","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin.","volume":"8","author":"Hanson","year":"2015","journal-title":"Circ Hear Fail"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a Prospective, Observational Cohort Study.","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians.","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation.","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/lv.2000.6145","article-title":"Liver transplantation for hereditary transthyretin amyloidosis.","volume":"6","author":"Suhr","year":"2000","journal-title":"Liver Transpl"},{"key":"R58-20250619","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","article-title":"Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry.","volume":"100","author":"Suhr","year":"2016","journal-title":"Transplantation"},{"key":"R59-20250619","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"R60-20250619","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejcts.2007.10.025","article-title":"Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.","volume":"33","author":"Sack","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"R61-20250619","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R62-20250619","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R63-20250619","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"R64-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179546817730322","article-title":"Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy.","volume":"11","author":"Sultan","year":"2017","journal-title":"Clin Med Insights Cardiol"},{"key":"R65-20250619","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"issue":"Suppl 1","key":"R66-20250619","first-page":"645","article-title":"1169Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy.","volume":"40","author":"Elliott","year":"2019","journal-title":"Eur Heart J"},{"key":"R67-20250619","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"key":"R70-20250619","first-page":"1","article-title":"FDA Approves VYNDAQEL\u00ae and VYNDAMAXTMfor use in patients with transthyretin amyloid cardiomyopathy, a rare and fatal disease.","author":"Danehy","year":"2019","journal-title":"Bus Wire"},{"key":"R71-20250619","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1253\/circj.CJ-19-0811","article-title":"A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis.","volume":"84","author":"Endo","year":"2019","journal-title":"Circ J"},{"key":"R72-20250619","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R73-20250619","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy.","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"R74-20250619","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history.","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R75-20250619","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy.","volume":"54","author":"Park","year":"2020","journal-title":"Ann Pharmacother"},{"key":"R76-20250619","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"R77-20250619","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"R78-20250619","first-page":"219","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"key":"R79-20250619","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"R81-20250619","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1182\/blood-2019-129269","article-title":"Rationale and design of a phase 3 Study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).","volume":"134","author":"Falk","year":"2019","journal-title":"Blood"},{"key":"R82-20250619","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R85-20250619","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis.","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"R86-20250619","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 Multicenter Study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR).","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"R87-20250619","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/nat.2019.0796","article-title":"Nonclinical safety profile of revusiran, a 1st-generation GalNAc-siRNA conjugate for treatment of hereditary transthyretin-mediated amyloidosis.","volume":"30","author":"Sutherland","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"R88-20250619","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.febslet.2015.02.020","article-title":"CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci.","volume":"589","author":"Mu","year":"2015","journal-title":"FEBS Lett"},{"key":"R89-20250619","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13506129.2017.1308348","article-title":"CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.","volume":"24","author":"Qiang","year":"2017","journal-title":"Amyloid"},{"key":"R90-20250619","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R91-20250619","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R92-20250619","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"R93-20250619","doi-asserted-by":"crossref","first-page":"e01371","DOI":"10.1002\/brb3.1371","article-title":"Advances in the treatment of hereditary transthyretin amyloidosis: a review.","volume":"9","author":"Gertz","year":"2019","journal-title":"Brain Behav"},{"key":"R94-20250619","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis.","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail"},{"key":"R95-20250619","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"suppl. 1","key":"R96-20250619","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13506129.2017.1291424","article-title":"Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.","volume":"24","author":"Azor\u00edn","year":"2017","journal-title":"Amyloid"},{"key":"R97-20250619","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"issue":"suppl 1","key":"R98-20250619","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study.","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"R99-20250619","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"key":"R100-20250619","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models.","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"R101-20250619","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","article-title":"Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.","volume":"1782","author":"Macedo","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"R102-20250619","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11739-018-1887-x","article-title":"Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study.","volume":"13","author":"Cappelli","year":"2018","journal-title":"Intern Emerg Med"},{"key":"R103-20250619","doi-asserted-by":"crossref","first-page":"e29933","DOI":"10.1371\/journal.pone.0029933","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \u201cin vivo\u201d evidence from FAP mice models.","volume":"7","author":"Ferreira","year":"2012","journal-title":"PLoS One"},{"key":"R104-20250619","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.febslet.2011.06.030","article-title":"Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation.","volume":"585","author":"Ferreira","year":"2011","journal-title":"FEBS Lett"},{"key":"R105-20250619","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:02:33Z","timestamp":1750356153000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000387","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}